【获批】石药拿下8亿大品种

米内网
Yesterday

精彩内容日前,国家药监局官网显示,石药欧意药业申报的4类仿制药富马酸伏诺拉生片获批生产并视同过评,原研产品2024年在中国三大终端六大市场(统计范围详见本文末)的销售额超过8亿元。今年以来,石药集团有1款1类新药、5款仿制药获批上市。富马酸伏诺拉生片是一种钾离子竞争性酸阻滞剂(P-CAB),用于治疗胃酸相关性疾病,包括反流性食管炎(RE)、胃溃疡、十二指肠溃疡等。米内网数据显示,富马酸伏诺拉生片已...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10